Resilia tissue developed by Edwards Lifesciences linked to long-term benefits
Aortic surgical valves treated with the Resilia tissue technology developed by Edwards Lifesciences are associated with significant improvements in long-term valve durability, according to new data presented at the Heart Valve Society’s annual meeting in Cairo, Egypt.
Resilia tissue treatments, developed as a way to help limit valve calcification, have been a major part of the Edwards device portfolio for many years now. In fact, the company estimates that more than 450,000 patients around the world have either undergone surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) with an Edwards Resilia valve.
This new propensity-matched comparison included data from nearly 1,000 SAVR patients and focused on eight-year rates of structural valve deterioration (SVD). Overall, SAVR patients who received Resilia SAVR valve were associated with higher rates of freedom from SVD (99.3% vs. 90.5%) and freedom from reoperation due to SVD (99.2% vs. 93.9%) after eight years than patients who received a non-Resilia SAVR valve.
“These highly anticipated data provide strong clinical evidence of the excellent durability of Resilia tissue in surgical valves,” lead author Tsuyoshi Kaneko, MD, chief of cardiac surgery at Washington University in St. Louis, said in a statement. “This level of performance is critical to reducing reinterventions and enabling more effective lifetime management for patients.”
“With patients of all ages living longer and demanding higher quality of life, the importance of lifetime management has never been greater,” added Larry Wood, Edwards’ corporate vice president and group president of TAVR and surgical structural heart. “This significant advancement in tissue technology highlights Edwards’ dedication to pioneering unique innovations and improving patient outcomes.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.